Cancer immunotherapy, particularly immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/PD-L1 axis, has revolutionized treatment for cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma. This evidence concerns the gene PDCD1 and cancer.